GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock DropsHealthcare technology company GE HealthCare Technologies (
NASDAQ:GEHC) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 7....
GE HealthCare reports first quarter 2026 financial results
GE HealthCare (Nasdaq: GEHC) today reported financial results for the first quarter ended March 31, 2026.
GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth
GE HealthCare (Nasdaq: GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company’s next chapter of growth and better serve patients and customers globally. The changes will also position the company to enhance execution, accelerate innovation, and create efficiencies. These changes are effective immediately.
GE HealthCare (GEHC) Q1 Earnings Report Preview: What To Look ForHealthcare technology company GE HealthCare Technologies (
NASDAQ:GEHC) will be reporting earnings this Wednesday before market open. Here’s what to look for....
GE HealthCare management to present at upcoming investor conferences
GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents
GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. FDA Fast Track designation expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs.
3 of Wall Street’s Favorite Stocks with Questionable FundamentalsWall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Hologic, Inc. (NASDAQ: HOLX): A New Chapter as a Women’s Health PowerhouseToday marks a definitive turning point for Hologic, Inc. (
NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks’ Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The PackLooking back on medical devices & supplies - imaging, diagnostics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Hologic...
GE HealthCare to announce first quarter 2026 results on April 29, 2026
GE HealthCare (Nasdaq: GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.
1 Value Stock on Our Buy List and 2 We Turn DownThe low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
The GE Renaissance: A Deep Dive into the Aerospace Powerhouse (2026 Research Report)As of today, April 3, 2026, GE Aerospace (
NYSE: GE) stands as a testament to one of the most successful corporate transformations in industrial history. No longer the sprawling, debt-laden conglomerate that once defined the American economy, the "new" GE is a streamlined, high-margin, pure-play aviation powerhouse. Following the final separation of its energy business, [...]
1 Profitable Stock to Target This Week and 2 We Turn DownNot all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To KnowWhat Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
GE HealthCare Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited
GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today that it received notice on March 30, 2026, of an unsolicited “mini-tender” offer by Potemkin Limited to purchase up to 100,000 shares of GE HealthCare common stock at a price of $45.80 per share in cash. Potemkin Limited’s offer price of $45.80 per share is approximately 34.80 percent lower than the $70.25 closing per share price of GE HealthCare’s common stock on March 18, 2026, the last trading day before the mini-tender offer appears to have commenced.
